A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif) In Patients With Relapsing Multiple Sclerosis

Trial Profile

A Randomized, Double-Blind, Double-Dummy, Parallel-Group Study To Evaluate The Efficacy And Safety Of Ocrelizumab In Comparison To Interferon Beta-1a (Rebif) In Patients With Relapsing Multiple Sclerosis

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Jul 2018

At a glance

  • Drugs Ocrelizumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Registrational; Therapeutic Use
  • Acronyms OPERA I
  • Sponsors Roche
  • Most Recent Events

    • 19 Jun 2018 Results of updated safety analysis from this and other three studies presented at the 4th Congress of the European Academy of Neurology.
    • 19 Jun 2018 Results of subgroup pooled analysis from OPERA I/II studies (NCT01247324/ NCT01412333) presented at the 4th Congress of the European Academy of Neurology
    • 13 Jun 2018 According to a Genentech media release, data from the Open-Label Extension part of this study will be presented at the 4th Congress of the European Academy of Neurology (EAN).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top